**References-**


1) Dannhardt, G.; Kiefer.W. Cyclooxygenase inhibitors-current status and Future prospects, *Eur.J.Med.Chem.* **2001**, *36,109*-126.

2) Singh,P.; Mittal,A. and Kumar,S. *Bioorganic & Medicinal Chemistry,* **2007,** 15, 3990–3996.

3) Hull,M.A. - Cyclooxygenase-2: How good is it as a target for cancer chemoprevention? *European Journal of Cancer,* **2005,** *41*, 1854–1863.

4) Singh,G.-Ranger, and Mokbel,K. *European journal of surgical oncology,* **2002**, 28: 729-737.

5) Basler,J.W. and Piazza.G.A. *The Journal Of Urology*. **2004,** Vol. 171, S59–S63.

6) Chell,S.; Kadi,A.; Williams,A.C.; Paraskeva,C. *Biochimica. Et. Biophysica. Acta..,* **2006,** 1766, 104–119.

7) Kawai,N.; Tsujii,M.; and Tsuji,S.Prostaglandins and other Mediators, **2002,** 68-69 ,187-196.

8) Dannenberg,A.J.; Altorki,N.K.; Boyle,J.O.; Dang,C.; Howe,L.R.; Weksler,B.B.; and Subbaramaiah,K. *THE LANCET Oncology,* **2001,** Vol 2. 240-244.

9) DeMaria,A.N.; and Weir,M.R. *Journal of Pain and Symptom Management*, **2003,** Vol. 25 No. 2S.

10) Bolli,R.; Shinmura,K.; Tang,X.L.; Kodani,E.; Xuan,Y.T.; Guo,Y. and Dawn,B. *Cardiovascular Research.,* **2002,** Volume 55, Issue 3 , Pages 506- 519.

11) Mahadevan,U.; Loftus,E.V.; Tremaine,W.J. and Sandborn,W.J. The *American Journal Of Gastroenterology.* 2002**,** 97, 4.

12) Catella,F.;Lawson, M.D. and Crofford,L.J. *The American Journal of Medicine.* **2001,** 28-32.

13) Talleley, J. J.; Brown, D. L.; Carter, J. S. J. Med. Chem., 2000, 43, 775.

14) Desiraju, G. R.; Gopalakrishnan, B.; Jetti, R. K. R.; Raveendra, D.; Jagarlapudi, A. R. P. Molecules 2000, 5, 945.

15) Habeeb, A. G.; Rao, P. N. P.; Knaus, E. E. J. Med. Chem. 2001, 44, 3039

16) Shrikhande, A. A.; Doshi, M. M.; Mody, S. B. U.S. Patent, 2002, 6, 403,

17) Liu, H.; Huang, X.; Shenn, J.; Luo, M.; Li, B.; Xiong, G.; Chen, J.; Shen, Y.; Yang, H.; Jiang, S.; Chen. K. J. Med. Chem. 2002, 45, 4816. 629.

18) Sarathy, K. P.; Giridhar, R.; Yadav, M. R. Ind. Drugs, 2003, 40, 9.

19) Uddin, J. M.; Rao, P. N. P.; Knaus, E. E. Bioorganic & Medicinal Chemistry 2003, 11, 5273–5280.

20) Talley, J. J.; Brown, D. L.; Carter, J. S. J. Med. Chem., 2000, 43, 775.

21) Vane, J.R.; Bakhle, Y.S. and Botting, R.M. *Annu. Rev. Pharmacol. Toxicol.*, **1998,** 38, 97.

22) Pruthi,R,S.; Derksen,E. And Gaston,K. Journal *Of Urology*, **2003,** 169, 2352–2359.

23) Emery,P. The American Journal of Medicine, **2001,**110, Issue 1.1, S42-S45.

24) Kunz,T. and Oliw,E.H. *Prostaglandins & other Lipid Mediators*, **1999,** 59, 1-235.

25) Kyrkanides,S.; Moore,A.H.; Olschowka,J.A.; Daeschner,J.C.; Williams,A.P.; Hansen,J.T. and O'Banion,K. *Molecular Brain Research*, **2002**, 104, 2, 159-169.

26) Aisen,P.S.Journal of Pain and Symptom Management , **2002,** 23, S35-S40.

27) Guo,J.S.; Cho,C.H.; Liu,E.S.L.; Choy,H.T.; Wang,J.Y. and Koo,M.W.L. *Toxicology and Applied Pharmacology*., **2002,** 183, 41–45.

28) Doret,M.; Mellier,G.; Benchaib,M.; Piacenza,J.M.; Gharib,C. and Pasquier,J.C. BJOG:An International Journal of Obstetr.s.and Gynaec, **2002, 109,9,** 983-988.

29) Singh,P.; Mittal,A. and Kumar,S. *Bioorganic & Medicinal Chemistry*, **2007,** 15, 3990–3996.

30) Mark A. Hull, *European Journal of Cancer*, **2005**, *41*, 1854–1863.

31) Singh,G.;Ranger and Mokbel,K. European journal of surgical oncology, 2002, 28: 729-737.

32) Basler,J.W. and Piazza,G.A. *The Journal Of Urology*. **2004,** Vol, 171, S59–S63.

33) Chell,S.; Kadi,A.; Williams,A.C.; Paraskeva,C. *Biochimica. Et. Biophysica. Acta..*, **2006,** 1766, 104–119.

34) Kawai,N.; Tsujii,M. and Tsuji,S. **2002,** 68-69 ,187-196.

35) Dannenberg,A.J.; Altorki,N.K.; Boyle,J.O.; Dang,C.; Howe,L.R.; Weksler,B. and Subbaramaiah,K. *THE LANCET Oncology*, **2001,** Vol 2. DeMaria,A.N. and Weir,M.R. *Journal of Pain and Symptom Management*, **2003,** Vol. 25 No. 2S.

36) Bolli,R.; Shinmura,K.; Tang,X.L.; Kodani,E.; Xuan,Y.T.; Guo,Y. and Dawn,B.cardiovascular Research 2002, volume55 , issue 3 , Pages 506-519.

37) Mahadevan,U.; Loftus,E.V.; Tremaine,W.J. and Sandborn,W.J. The American Journal Of Gastroenterology. 2002, 97, 4.

38) Catella,F.;Lawson, M.D. and Crofford,L.J. The American Journal of Medicine, 2001, 28-32.

39) Karim, S.; Habib, A.; Levy-Tolendano, S.; Maclouf, J. JBC Online: **1996**; 12042-12048.

40) Sengupta, S. *Ind. J. Pharmacol.*, **1999,** 31, 322.

41) Cai, Q.; Lanting, L.; Natarajan R.; *Am. J. Physiol. Cell Physiology*; **2004**; C-717-C714.

42) Borlon, C.; Vankoningsloo, S.; Godard, P.; Florence, D.; Toussaint, D. Mech Ageing Dev; 2007; 180,68,755.

43) Halgren,T.,A. Merck Molecular Force Field. III. Molecular Geometries and. Vibrational Frequencies, J. Comp. Chem. 17 (1996) 520–552.

44) Ohtawara,K. and Teramae,H. "Study on optimization of molecular structure using Hamiltonian algorithm", Chemical physics Letters, 390 (2004) 84-88.

45) Bhandari,S.V.; Bothara,K.G.; Gore,S.; Khachane,C.; Sarkate,A.; Patil,A. Proceedings of the European Symposium on Quantitative Structure-Activity Relationships & Omics Technologies and Systems Biology, Uppsala,Sweden, Sept. (2008)

46) Ajmani,S.; Jadhav,K.; and Kulkarni,S. "Three-Dimensional QSAR Using the k-Nearest Neighbo Method and Its Interpretation" J. Comp. Inf. & Model, 2006, 46, 24–31.

47) Charifson,P.S. Protein Ligand interactions from molecular recognition to Drug Design, Practical Application of Computer-aided drug design, MARCEL DEKKER INC, (1997), 112-113.

48) Lipinski,C.A.;Lombardo,F.B.;Dominy,W. and Feeney,P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug. Deliv. Rev., 1997, 23-25.

49) Glide. Molecular Docking Tool of Schrodinger Inc., Version 5.0, New York, USA.

50) Murray,M.D. and Brater,D.C. Renal Toxicity of Non steroidal anti inflammatory Drugs, Annu. Rev. Pharm. Toxicol. 32(1993) 435–465.

51) Pommery, N. ; Taverne, T. ; Telliez, A. ; Goossens, L. ; Charlier, C. ; Pommery, J. ; Goossens, J. F. ; Houssin, R. ; Durant, F. ; He´nichart, J. Med. Chem 2004, 47, 6195-6206.

52) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, P. C. J. Med. Chem. 1997, 40, 1347.

53) Vogel, W.H.;Scholkens, B.A.; Sandow, J.; Muller, G.; Vogel,W.F.In Drug Discovery and evaluation: Pharmacological assays, 6th ed, Springer Verlag Berlin Heidelberg,New York,2002,382-384,406-409, 416-417.

54) Grover, J.K.In Experiments in Pharmacy and Pharmacology, Vol II, 1st ed, CBS Publishers and distributors, New Delhi, 176-177.